series-b
Stage
2020
Founded
1
Investors
About
ImmunoGenesis is a clinical-stage biopharmaceutical company focused on developing immunotherapies for the treatment of cancer, specifically targeting cold tumors resistant to existing treatments. The company’s lead product, IMGS-001, is a cytotoxic immune checkpoint inhibitor designed to overcome immune resistance mechanisms in tumors.
Explore ImmunoGenesis's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.